BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2012;30:2015-25. [PMID: 22187203 DOI: 10.1007/s10637-011-9776-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
2 Iwazawa J, Ohue S, Hashimoto N, Mitani T. Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin. Cancer Manag Res. 2012;4:113-119. [PMID: 22570565 DOI: 10.2147/cmar.s30431] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M, Matsumoto N, Nakagawara H, Ohshiro S, Yamamoto T. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results. Hepatol Res. 2016;46:E60-E69. [PMID: 25974615 DOI: 10.1111/hepr.12527] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
4 Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y, Koshikawa Y. A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Rep Oncol 2011;4:327-35. [PMID: 21738504 DOI: 10.1159/000330106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Gu W, Gaborieau M, Huynh VT, de Souza PL, Stenzel MH. Functionalization of microspheres with malonates using Michael Addition as a pathway to create a drug delivery system for platinum drugs for the treatment of liver cancer. Polymer 2011;52:5993-6002. [DOI: 10.1016/j.polymer.2011.10.054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
6 Ikeda K, Kawamura Y, Kobayashi M, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma: Warmed miriplatin for multiple HCC. Hepatol Res 2017;47:632-40. [DOI: 10.1111/hepr.12782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sawant A, Kamath S, Kg H, Kulyadi GP. Solid-in-Oil-in-Water Emulsion: An Innovative Paradigm to Improve Drug Stability and Biological Activity. AAPS PharmSciTech 2021;22:199. [PMID: 34212274 DOI: 10.1208/s12249-021-02074-y] [Reference Citation Analysis]
8 Li X, He G, Su F, Chu Z, Xu L, Zhang Y, Zhou J, Ding Y. Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma. Asian J Pharm Sci 2020;15:739-51. [PMID: 33363629 DOI: 10.1016/j.ajps.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Handa T, Imai Y, Sugawara K, Chikayama T, Nakazawa M, Ando S, Hamaoka K, Inao M, Nakayama N, Mochida S. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin: TACE for HCC with miriplatin vs epirubicin. Hepatol Res 2014;44:1072-80. [DOI: 10.1111/hepr.12225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
10 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
11 Yasui K, Takashima H, Miyagawa M, Miyazawa K, Ochiai T, Mukaisho K, Amaike H, Ueda K, Morikawa J, Otsuji E, Yoshikawa T. Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. Hepatol Res 2013;43:1093-9. [PMID: 23347452 DOI: 10.1111/hepr.12059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 de Silva S, Mackie S, Aslan P, Cade D, Delprado W. Histological Comparison of Kidney Tissue Following Radioembolization with Yttrium-90 Resin Microspheres and Embolization with Bland Microspheres. Cardiovasc Intervent Radiol 2016;39:1743-9. [PMID: 27743088 DOI: 10.1007/s00270-016-1482-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol 2012;12:127. [PMID: 22994941 DOI: 10.1186/1471-230X-12-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
14 Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. 2011;Epub ahead of print. [PMID: 21976133 DOI: 10.1007/s00535-011-0475-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
15 Iwazawa J, Ohue S, Yasumasa K, Mitani T. Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver. World J Radiol 2010; 2(12): 468-471 [PMID: 21225002 DOI: 10.4329/wjr.v2.i12.468] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R, Sakamaki A, Abe S, Kawai H, Suda T, Yamagiwa S, Terai S. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. World J Clin Cases 2017; 5(6): 238-246 [PMID: 28685137 DOI: 10.12998/wjcc.v5.i6.238] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Zhang Y, Hu D, Han S, Yan G, Ma C, Wei C, Yu M, Li D, Sun Y. Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery. Exp Biol Med (Maywood) 2016;241:1169-76. [PMID: 26743756 DOI: 10.1177/1535370215625473] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Oguro S, Hashimoto S, Tanaka T, Inoue M, Nakatsuka S, Kuribayashi S, Asakura K, Kawachi S, Tanabe M, Kitagawa Y, Ebinuma H, Saito H, Hibi T. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin–lipiodol suspension for hepatocellular carcinoma. Jpn J Radiol 2012;30:735-42. [DOI: 10.1007/s11604-012-0116-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
19 Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011;80:188-194. [PMID: 21709428 DOI: 10.1159/000328749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
20 Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2018; 10(7): 485-495 [PMID: 30079135 DOI: 10.4254/wjh.v10.i7.485] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc Intervent Radiol. 2013;36:1023-1029. [PMID: 23238851 DOI: 10.1007/s00270-012-0537-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
22 Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol. 2012;42:175-182. [PMID: 22210921 DOI: 10.1093/jjco/hyr189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Ishikawa T, Abe S, Watanabe T, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma. Mol Clin Oncol 2016;5:511-6. [PMID: 27882236 DOI: 10.3892/mco.2016.998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Yamanaka T, Takaki H, Nakatsuka A, Uchida K, Junji U, Fujimori M, Hasegawa T, Yoneda M, Shiraishi T, Sakuma H, Yamakado K. Radiofrequency Ablation After Arterial Injection of Miriplatin–Iodized Oil Suspension Into Swine Liver: Ablative Zone Size and Tissue Platinum Concentration. Cardiovasc Intervent Radiol 2014;37:1047-52. [DOI: 10.1007/s00270-013-0779-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Yasui D, Yamane A, Itoh H, Kobayashi M, Kumita SI. In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model. PLoS One 2020;15:e0222553. [PMID: 32756561 DOI: 10.1371/journal.pone.0222553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Watanabe Y, Ogawa M, Kumagawa M, Hirayama M, Miura T, Matsumoto N, Nakagawara H, Yamamoto T, Moriyama M. Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. J Ultrasound Med 2020;39:431-40. [PMID: 31436341 DOI: 10.1002/jum.15118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Štarha P, Vančo J, Trávníček Z. Platinum iodido complexes: A comprehensive overview of anticancer activity and mechanisms of action. Coordination Chemistry Reviews 2019;380:103-35. [DOI: 10.1016/j.ccr.2018.09.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
28 Kumasawa F, Miura T, Takahashi T, Endo D, Ohki T, Nakagawara H, Maruoka S, Tsujino I, Masahiro O, Gon Y, Takahashi N, Moriyama M, Hashimoto S. A case of miriplatin-induced lung injury. Journal of Infection and Chemotherapy 2016;22:486-9. [DOI: 10.1016/j.jiac.2016.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
29 Liu S, Li Y, Wang X, Ma J, Zhang L, Xia G. Preparation, Characterization, and Antitumor Activities of Miriplatin-Loaded Liposomes. Journal of Pharmaceutical Sciences 2016;105:78-87. [DOI: 10.1016/j.xphs.2015.10.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, Toshima F, Matsui O. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. 2012;30:263-270. [PMID: 22223074 DOI: 10.1007/s11604-011-0043-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
31 Tomozawa Y, Nitta N, Ohta S, Otani H, Watanabe S, Sonoda A, Tsuchiya K, Nitta-seko A, Takahashi M, Murata K. Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model. Jpn J Radiol 2013;31:662-7. [DOI: 10.1007/s11604-013-0231-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Matsumoto T, Endo J, Hashida K, Ichikawa H, Kojima S, Takashimizu S, Watanabe N, Yamagami T, Hasebe T. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations. Minim Invasive Ther Allied Technol. 2015;24:94-100. [PMID: 25263680 DOI: 10.3109/13645706.2014.951657] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
33 Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int 2014;2014:359296. [PMID: 25276780 DOI: 10.1155/2014/359296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Vinh NQ, Naka S, Cabral H, Murayama H, Kaida S, Kataoka K, Morikawa S, Tani T. MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model. Int J Nanomedicine 2015;10:4137-47. [PMID: 26203241 DOI: 10.2147/IJN.S81339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
35 Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. Gut Liver. 2013;7:246-251. [PMID: 23560163 DOI: 10.5009/gnl.2013.7.2.246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, Seki K, Honma T, Nemoto T, Takeda K. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS One. 2014;9:e103009. [PMID: 25047920 DOI: 10.1371/journal.pone.0103009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
37 Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, Fujita N, Morita K, Honda H. Hemodynamic changes under balloon occlusion of hepatic artery: predictor of the short-term therapeutic effect of balloon-occluded transcatheter arterial chemolipiodolization using miriplatin for hepatocellular carcinoma. Springerplus. 2016;5:157. [PMID: 27026854 DOI: 10.1186/s40064-016-1880-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
38 Tanaka H, Okamoto K, Sato Y, Tanaka T, Tomonari T, Nakamura F, Fujino Y, Mitsui Y, Miyamoto H, Muguruma N, Morita A, Ikushima H, Takayama T. Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. J Gastroenterol 2020;55:1072-86. [DOI: 10.1007/s00535-020-01705-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Watanabe S, Nitta N, Ohta S, Sonoda A, Otani H, Tomozawa Y, Nitta-Seko A, Tsuchiya K, Tanka T, Takahashi M. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol. 2012;35:399-405. [PMID: 21584842 DOI: 10.1007/s00270-011-0172-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
40 Kubota K, Hidaka H, Nakazawa T, Okuwaki Y, Yamane K, Inoue T, Uojima H, Takada J, Tanaka Y, Shibuya A, Fujii K, Woodhams R, Matsunaga K, Kokubu S, Koizumi W. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma: TACE with miriplatin in Japanese HCC patients. Hepatol Res 2018;48:E98-E106. [DOI: 10.1111/hepr.12933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
41 Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013;43:942-949. [PMID: 23301851 DOI: 10.1111/hepr.12041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
42 Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Ohki T, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. Hepatol Res 2013;43:1100-4. [PMID: 23347354 DOI: 10.1111/hepr.12050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]